Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Johnson and Johnson
AstraZeneca
Harvard Business School

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Nelarabine - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for nelarabine and what is the scope of patent protection?

Nelarabine is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for nelarabine. One supplier is listed for this compound.

Summary for nelarabine
Recent Clinical Trials for nelarabine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 1/Phase 2
National Cancer Institute (NCI)Phase 1/Phase 2
Emory UniversityPhase 1

See all nelarabine clinical trials

Pharmacology for nelarabine
Synonyms for nelarabine
(2R,3R,4S,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol
(2R,3S,4S,5R)-2-(2-amino-6-methoxy-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(2-Amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
(2R,3S,4S,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
(2R,3S,4S,5R)-2-(2-amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(2-azanyl-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(hydroxymethyl)-5-(2-imino-6-methoxy-3,9-dihydro-2H-purin-9-yl)oxolane-3,4-diol
032N299
121032-29-9
2-(2-Amino-6-methoxy-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2-Amino-6-methoxy-9-(beta-D-arabinofuranosyl)-9H-purine
2-Amino-6-methoxy-9-b-D-arabinofuranosyl-9 H-purine
2-Amino-6-methoxy-9-b-D-arabinofuranosyl-9H-purine
2-Amino-6-methoxy-9-beta-D-arabinofuranosyl-9H-purine
2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine
506U
506U78
6-O-Methyl Guanosine
60158CV180
9-?-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
9-(beta-D-arabinofuranosyl)-6-methoxy-9H-purin-2-amine
9-beta -D-arabinofuranosyl-2-amino-6-methoxy-9H-purine
9-beta-D-arabinofuranosyl-2-amino-6-methoxy-9 H-purine
9-beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine
9H-Purin-2-amine, 9beta-D-arabinofuranosyl-6-methyl-
A804639
AB01274773_02
AB01274773-01
ABP000601
AC1MHTJS
AJ-45735
AK-25325
AKOS015852325
AKOS015920191
Arranon
Arranon (GlaxoSmithKline)
Arranon (TN)
Arranon/
Arranon|||Nelzarabine|||GW-506U78|||(2R,3S,4S,5R)-2-(2-Amino-6-methoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
ArranonG
AS-47664
Atriance
AX8031634
BCP9000318
BCPP000392
BR-25325
BRD-K84466663-001-01-3
C-58277
CAS-121032-29-9
CHEBI:63612
CHEMBL1201112
CN0033
CS-1607
D05134
DB01280
DSSTox_CID_26842
DSSTox_GSID_46842
DSSTox_RID_81952
DTXSID6046842
FT-0650169
FT-0671804
GTPL7090
GW 506U78
GW-506U
GW-506U78
GW506U78
HMS3715I16
HY-13701
IXOXBSCIXZEQEQ-UHTZMRCNSA-N
J10096
KB-274813
KB-58122
MAY
MLS003915614
MLS004774135
MLS006010906
MolPort-006-167-760
NCGC00181098-01
NCGC00274059-01
Nelarabine (Arranon)
Nelarabine (JAN/USAN/INN)
Nelarabine [USAN:INN:BAN]
Nelzarabine
Nelzarabine (USAN)
NSC 686673
NSC-686673
NSC-755985
NSC755985
S-7406
S1213
SB19492
SC-28312
SCHEMBL18820
SMR002544682
SR-01000931847
SR-01000931847-3
ST2419746
SW218086-2
Tox21_112714
Tox21_112714_1
U78
UNII-60158CV180
ZINC3823492

US Patents and Regulatory Information for nelarabine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for nelarabine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;INTRAVENOUS 021877-001 Oct 28, 2005   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Express Scripts
Medtronic
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.